Biotech · Private company
Biotie Therapies Inc.
Track this companyFree. Adds Biotie Therapies Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- Levodopa (L-dopa)Phase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- tozadenantPhase 3 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- TozadenantPhase 3 · Idiopathic Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Tozadenant (SYN115) 120 mg BIDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Tozadenant (SYN115) 180 mg BIDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Tozadenant (SYN115) 240 mg BIDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Tozadenant (SYN115) 60 mg BIDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SYN111Phase 2 · Generalized Anxiety DisorderClinicalTrials.gov · fetched Nov 12, 2026
- SYN120Phase 2 · Parkinson's Disease Dementia (PDD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.PHASE3 · TERMINATED · started Apr 10, 2017ClinicalTrials.gov NCT03051607 · fetched Nov 12, 2026
- Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsPHASE3 · TERMINATED · started Jul 1, 2015ClinicalTrials.gov NCT02453386 · fetched Nov 12, 2026
- SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)PHASE2 · COMPLETED · started Dec 22, 2014ClinicalTrials.gov NCT02258152 · fetched Nov 12, 2026
- Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffPHASE2_PHASE3 · COMPLETED · started Mar 1, 2011ClinicalTrials.gov NCT01283594 · fetched Nov 12, 2026
- Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)PHASE2 · COMPLETED · started Mar 1, 2008ClinicalTrials.gov NCT00595231 · fetched Nov 12, 2026